December 10, 2020 11:02 AM EST

Recall report: AvKARE somehow mixed its antidepressant and erectile dysfunction meds; Torrent pulls thrombocytosis drug

Conner Mitchell

Any number of issues can lead to an FDA recall, but here’s one you don’t see every day: A third-party manufacturer for Tennessee-based AvKARE apparently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recall report: AvKARE somehow mixed its antidepressant and erectile dysfunction meds; Torrent pulls thrombocytosis drug

Conner Mitchell

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Re­call re­port: AvKARE some­how mixed its an­ti­de­pres­sant and erec­tile dys­func­tion meds; Tor­rent pulls throm­bo­cy­to­sis drug

Conner Mitchell

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Recall report: AvKARE somehow mixed its antidepressant and erectile dysfunction meds; Torrent pulls thrombocytosis drug

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?